Immunomedics (NASDAQ:IMMU) has earned a consensus rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $21.00.
Several equities research analysts recently issued reports on the company. BidaskClub lowered Immunomedics from a “buy” rating to a “hold” rating in a research report on Saturday, March 17th. Zacks Investment Research lowered Immunomedics from a “hold” rating to a “sell” rating in a research report on Saturday, February 17th. TheStreet raised Immunomedics from a “d” rating to a “c-” rating in a research report on Friday, February 9th. ValuEngine raised Immunomedics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Jefferies Group upped their price target on Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th.
Shares of IMMU stock traded down $0.69 on Friday, hitting $13.94. 1,608,244 shares of the stock traded hands, compared to its average volume of 1,966,683. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20. The firm has a market cap of $2,310.89, a P/E ratio of -17.21 and a beta of 1.62. Immunomedics has a 1-year low of $5.00 and a 1-year high of $18.93.
Immunomedics (NASDAQ:IMMU) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.09). The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $0.90 million. research analysts forecast that Immunomedics will post -0.96 EPS for the current fiscal year.
In other Immunomedics news, Director David M. Goldenberg sold 20,000 shares of the stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $17.50, for a total value of $350,000.00. Following the sale, the director now directly owns 1,774,285 shares of the company’s stock, valued at $31,049,987.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director David M. Goldenberg sold 17,729 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total value of $302,988.61. Following the completion of the sale, the director now directly owns 1,774,285 shares in the company, valued at $30,322,530.65. The disclosure for this sale can be found here. Insiders sold 77,729 shares of company stock worth $1,342,589 over the last ninety days. 14.80% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. American International Group Inc. increased its position in Immunomedics by 8.1% in the third quarter. American International Group Inc. now owns 68,533 shares of the biopharmaceutical company’s stock worth $958,000 after buying an additional 5,125 shares during the period. SG Americas Securities LLC increased its position in Immunomedics by 27.2% in the third quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 5,631 shares during the period. Calton & Associates Inc. acquired a new stake in Immunomedics in the fourth quarter worth $135,000. NEXT Financial Group Inc increased its position in Immunomedics by 9.6% in the fourth quarter. NEXT Financial Group Inc now owns 121,350 shares of the biopharmaceutical company’s stock worth $1,961,000 after buying an additional 10,600 shares during the period. Finally, Xact Kapitalforvaltning AB acquired a new stake in Immunomedics in the fourth quarter worth $193,000. 74.51% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Immunomedics (IMMU) Given Average Rating of “Hold” by Analysts” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/immunomedics-immu-given-average-rating-of-hold-by-analysts.html.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.